0001209191-22-011841.txt : 20220222
0001209191-22-011841.hdr.sgml : 20220222
20220222174406
ACCESSION NUMBER: 0001209191-22-011841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220218
FILED AS OF DATE: 20220222
DATE AS OF CHANGE: 20220222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Brendan
CENTRAL INDEX KEY: 0001857492
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 22659638
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-18
0
0001674416
CRISPR Therapeutics AG
CRSP
0001857492
Smith Brendan
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
58.29
2022-02-18
4
A
0
30000
0.00
A
2032-02-18
Common Shares
30000
30000
D
Restricted Stock Units
2022-02-18
4
A
0
15300
0.00
A
Common Shares
15300
15300
D
This option was granted on February 18, 2022 with respect to 30,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
/s/ Michael Esposito, attorney-in-fact
2022-02-22